



## Extracellular Vesicles in Drug Delivery System

Guest Editor:

### Dr. Hongbo Chen

Associate Professor of  
Pharmacology, School of  
Pharmaceutical Sciences  
(Shenzhen), Shenzhen Campus of  
Sun Yat-sen University, Shenzhen  
518107, China

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

The special issue will focus on extracellular vesicles (EVs) - based drug delivery, including microvesicles, exosomes, ectosomes, apoptotic bodies, bacterial EVs plant EVs and milk EVs and so on. The focus areas of this topic include but are not limited to:

- Progress in isolation and purification of extracellular vesicles.
- Gene engineering and chemical modification of extracellular vesicles to improve their targeting or function.
- Advances in dosage form, drug delivery routes and pharmacokinetics of extracellular vesicles.
- Technical progress of exosomes loading small molecule drugs, protein and polypeptide drugs and nucleic acid drugs
- Application of exosomes or drug loaded extracellular vesicles in tumor therapy, immunotherapy, tissue damage repair and other diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)